BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 10759015)

  • 61. [Properties and virus safety of a pasteurized antithrombin III concentrate].
    Karges HE; Fuhge P; Heimburger N
    Arzneimittelforschung; 1987 Jul; 37(7):756-8. PubMed ID: 2823838
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography.
    Roberts PL; Walker CP; Feldman PA
    Vox Sang; 1994; 67 Suppl 1():69-71. PubMed ID: 8091741
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Viral infectivity of albumin and plasma protein fraction.
    Erstad BL
    Pharmacotherapy; 1996; 16(6):996-1001. PubMed ID: 8947970
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Factor VIII fractionation on aminohexyl Sepharose with possible reduction in hepatitis B antigen.
    Austen DE; Smith JK
    Thromb Haemost; 1982 Aug; 48(1):46-8. PubMed ID: 6813994
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Chromatographic removal of viruses from plasma derivatives.
    Burnouf T
    Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Non-enveloped viruses transmitted by blood and blood products.
    Robertson BH; Erdman DD
    Dev Biol (Basel); 2000; 102():29-35. PubMed ID: 10794088
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.
    Nübling CM; Chudy M; Volkers P; Löwer J
    Transfusion; 2006 Nov; 46(11):1886-91. PubMed ID: 17076842
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
    Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
    Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
    Schwinn H; Smith A; Wolter D
    Arzneimittelforschung; 1989 Oct; 39(10):1302-5. PubMed ID: 2514695
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pathogen safety of plasma-derived products - Haemate P/Humate-P.
    Gröner A
    Haemophilia; 2008 Nov; 14 Suppl 5(Suppl 5):54-71. PubMed ID: 18786011
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Viral safety of C1-inhibitor NF.
    Terpstra FG; Kleijn M; Koenderman AH; Over J; van Engelenburg FA; Schuitemaker H; van 't Wout AB
    Biologicals; 2007 Jun; 35(3):173-81. PubMed ID: 17071103
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Viral validation of the manufacturing process of high purity albumin from placentas.
    Grandgeorge M; Véron JL
    Dev Biol Stand; 1993; 81():237-44. PubMed ID: 8174808
    [TBL] [Abstract][Full Text] [Related]  

  • 74. H5N1 influenza virus and the safety of plasma products.
    Kreil TR; Unger U; Orth SM; Petutschnig G; Kistner O; Poelsler G; Berting A
    Transfusion; 2007 Mar; 47(3):452-9. PubMed ID: 17319825
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Plasma-derived biological medicines used to promote haemostasis.
    Ofosu FA; Freedman J; Semple JW
    Thromb Haemost; 2008 May; 99(5):851-62. PubMed ID: 18449414
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Possibilities of virus inactivation of pooled fresh plasma with tri-n-butylphosphate (TNBP) detergents (SD procedure)].
    Gürtler L
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():77-9. PubMed ID: 8000260
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evidence of multiple hepatitis virus infections in autopsied materials of intravenous drug addicts.
    Schleicher S; Schieffer M; Jürgens S; Wehner HD; Flehmig B
    Ig Sanita Pubbl; 2005; 61(5):435-50. PubMed ID: 17214028
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fibrin glue safety: inactivation of potential viral contaminants by pasteurization of the human plasma components.
    Hilfenhaus J; Weidmann E
    Arzneimittelforschung; 1985; 35(11):1617-9. PubMed ID: 3004516
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Factor VIII concentrate from cold sterilized human plasma.
    Stephan W; Prince AM; Kotitschke R
    Dev Biol Stand; 1983; 54():491-5. PubMed ID: 6418593
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The incidence of HTLV-III/LAV seroconversion and non-A, non-B hepatitis in recipients of plasma products.
    Piszkiewicz D; Kingdon H; Lee ML; Hooper J
    Dev Biol Stand; 1987; 67():327-31. PubMed ID: 2440745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.